Biotech Values

[DewDiligence]

Fishy PR from CHRS on Neulasta FoB:

http://finance.yahoo.com/news/coherus-announces-topline-results-chs-200827263.html

Coherus BioSciences, Inc…today reported the results from its pharmacokinetic and pharmacodynamic (PK/PD) clinical study of CHS-1701, a pegfilgrastim (Neulasta) biosimilar candidate.

This study met its primary PD endpoints of absolute neutrophil count (ANC). In terms of PK parameters, the study also met bioequivalence for Cmax. The Area Under the Curve (AUC) portion of the PK results are still under review. [What the heck does that mean?]

Given these overall positive results, Coherus remains on track for its planned BLA filing in the first quarter of 2016.

Very odd language. For an FoB, you don’t want “overall positive results”—you want positive results, period. The stock should be lower, not higher, in AH trading, IMO.